Newswire (Published: Thursday, January 3, 2019, 11:00:00 AM CST, Received: Thursday, January 3, 2019, 1:45:51 PM CST)

Word Count: 377

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from San Francisco, California, by NewsRx correspondents, research stated, "Apalutamide (ARN-509) is a second-generation androgen receptor (AR) antagonist that was developed to inhibit AR-mediated prostate cancer cell proliferation. Following the initial promising clinical efficacy results in phase I and II clinical trials of patients with metastatic castrate-resistant prostate cancer (CRPC), apalutamide has been investigated in several phase III trials."

Our news editors obtained a quote from the research from the University of California - San Francisco, "Particular interest has focused on the development of effective therapy for the prevention of disease progression in patients with nonmetastatic (nm or M0) CRPC, especially patients who have a rapid prostate-specific antigen (PSA) doubling time that is indicative of shorter bone metastasis-free survival and associated with significant morbidity and mortality. The results from the phase III SPARTAN trial were recently published and reported a significant benefit of apalutamide relative to placebo in patients with nmCRPC and a high risk of metastatic progression. The study noted marked improvement in the primary endpoint of metastasis-free survival as well as several relevant secondary clinical endpoints, including time to symptomatic progression. These results led to the United States Food and Drug Administration (US FDA) approval of apalutamide in the nmCRPC setting in February 2018."

According to the news editors, the research concluded: "This review summarizes the clinical development of apalutamide, culminating with the pivotal SPARTAN trial as well as other phase III trials which may further expand potential indications for this agent in the near future."

For more information on this research see: Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Therapeutic Advances In Urology, 2018;10(12):445-454. (Sage Publications - www.sagepub.com/; Therapeutic Advances In Urology - tau.sagepub.com)

The news editors report that additional information may be obtained by contacting V.S. Koshkin, Division of Hematology, Oncology, Dept. of Medicine, University of California San Francisco, 550 16th Street, Box 3211, San Francisco, CA 94158, United States (see also Oncology - Prostate Cancer).

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of California
US Food and Drug Administration

Industries

Pharmaceuticals

Places

North America
United States
Americas
California
San Francisco

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices
            Urology
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
                  Drug Testing and Approval Process
      Treatments and Therapies
            Medicinal Drugs
                  Drug Testing and Approval Process